106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2021 All rights reserved.
ASCOSAL02212
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO® practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines do
not account for individual variation among patients. is pocket guide does not purport to suggest any
particular course of medical treatment. Use of the practice guidelines and this resource are voluntary.
e practice guidelines and additional information are available at www.asco.org/head-neck-cancer-
guidelines. Copyright © 2021 by American Society of Clinical Oncolog y. All rights reserved.
Recommendation Grading
Type Evidence Quality Strength of Recommendation
EB Evidence-based H High Strong
CB/
FC
Consensus-based/
Formal Consensus
I Intermediate Moderate
IC Informal consensus L Low Weak
N No recommendation Ins Insufficient
Abbreviations
CT, computed tomography; IV, intravenous; MSRSGC, Milan System for Reporting Salivary Gland
Cytopathology; MRI, magnetic resonance imaging ; MSI-H, microsatellite instability-high; PET/CT,
positron emission tomography-computed tomography; ROHM, risk of high grade malignancy; ROM,
risk of malignancy; RT, radiotherapy; SBRT, stereotactic body radiation; SGM, salivary gland malignancy
Source
Geiger JL, Ismaila N, Beadle B, et al. Management of Salivary Gland Malignancy. J Clin Oncol.
2021 April 26. doi: 10.1200/JCO.21.00449
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical
tools and resources, is available at www.asco.org/head-neck-cancer-guidelines.
